OHE OHE
Close
OHE
Newsletter SignupSubscribe

Biosimilars

Biosimilars have similar, but not identical, structures to branded biologic drugs. Being comparable, but not interchangeable, they can differ in cost-effectiveness and accessibility. Increased competition, however, can reduce healthcare system costs.

Featured

Filter results by

Theme
Select the product option you would like to filter Theme
Tag
Select the product option you would like to filter Tag
Date 1
Select the product option you would like to filter Date
Date From
Date To
Author
Select the product option you would like to filter Author
Content type
Select the product option you would like to filter Content type
  • News
  • December 2014

Biosimilar Competition: Lessons from Europe and Prospects for the US

Read more
  • News
  • June 2014

Spotlight on OHE: NICE, Biosimilars, HTA

Read more
  • News
  • April 2014

Biosimilars and HTA: Results of a Roundtable Discussion

Read more
  • News
  • January 2011

The Market for Biosimilars

Read more
amerflag7-4-10
  • News
  • July 2010

Estimating US Savings from Biosimilars

Read more
euflags6-29-10
  • News
  • July 2010

EU Approval of Biosimilars

Read more
Factors influencing a potential price war
  • News
  • June 2010

Biosimilars’ Price Dynamic in Europe

Read more
  • News
  • June 2010

Price Competition and Biosimilars

Read more
Prof Adrian Towse
  • News
  • June 2010

Biosimilars: Modelling the Evolution of the Market

Read more
Prof Henry Grabowski
  • News
  • June 2010

Biosimilars and Data Exclusivity

Read more
Load More